Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have received an infusion of tisagenlecleucel (a type of cell therapy) through a commercial or managed access program, or through a special pathway such as when the product was made for commercial use but did not fully meet standard specifications.
- You have agreed to have your health data collected as part of this study.
Who may not be able to join:
- You are already enrolled, or plan to be enrolled, in a specific Novartis long-term follow-up study called CCTL019A2205B.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The type and frequency of AEs, ADRs, SAEs, SADRs, UAEs, UADRs, USAEs, USADRs, AESI; Identify participants for chimeric antigen receptor (CAR) transgene detection and/or CAR surface expression (if applicable).; Identify presence of replication competent lentivirus (RCL) in blood or tissues
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.